Abstract: Genetic alterations in the TP63 (GenBank: NC_000003.12,
ID: 8626) and CCR5 (receptor 5 chemokine co-receptor)
(GenBank: NC_000003.12, ID: 1234) genes may increase the
risk of developing breast cancer. The aim of this study was
to investigate the probable involvement of polymorphisms
rs17506395 in the TP63 (tumour protein 63) gene and the
CCR5Δ32 mutation in the occurrence of breast cancer in
Burkina Faso. This case–control study included 72 patients
and 72 controls. Genotyping of SNP rs17506395 (TP63) was
performed by polymerase chain reaction–restriction fragment
length polymorphism, and genotyping of the CCR5Δ32
mutation was performed by allele-specific oligonucleotide
polymerase chain reaction. For SNP rs17506395 (TP63), the
genotypic frequencies of wild-type homozygotes (TT) and heterozygotes
(TG) were, respectively, 27.72 and 72.22% in cases
and 36.11 and 63.89% in controls. No mutated homozygotes
(GG) were observed. For the CCR5Δ32 mutation, the genotypic
frequencies of wild-type homozygotes (WT/WT) and heterozygotes
(WT/Δ32) were 87.5 and 13.5%, respectively, in the
cases and 89.29 and 10.71%, respectively, in the controls. No
mutated homozygotes (Δ32/Δ32) were observed. None of the
polymorphisms rs17506395 of the TP63 gene (OR = 1.47, 95%
CI = 0.69–3.17, P = 0.284) and the CCR5Δ32 mutation (OR = 1.32,
95% CI = 0.46–3.77; P = 0.79) were associated with the occurrence
of breast cancer in this study.

breast cancer TP63 CCR5 polymorphism Burkina Faso